← Editorial teamCoverage area
Evidence reviewer
This GLP articles covering Randomized trial design and endpoints, FDA prescribing information and label changes, Reported adverse events and dropout rates, Dose-response and titration schedules, Compounded versus FDA-approved formulations, Reading a study's limitations section.
Published by This GLP Editorial Team. This collection brings together sourced articles on what the trials measured, in whom, at what dose, and for how long. These pages explain available evidence; they do not provide a clinical opinion or claim firsthand treatment experience.
Coverage
- Randomized trial design and endpoints
- FDA prescribing information and label changes
- Reported adverse events and dropout rates
- Dose-response and titration schedules
- Compounded versus FDA-approved formulations
- Reading a study's limitations section
Articles in this collection
77 pieces- Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials ShowEvidence
- Does Tirzepatide Cause Skin Sensitivity? The Allodynia Reports, CountedSafety
- Should You Stop Ozempic Before a Colonoscopy? What Bowel-Prep Studies FoundSafety
- Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same ExposureFormats
- How Long Does Zepbound Stay in Your System? About a MonthSafety
- How Do You Avoid Ozempic Face? No Tested Way to Prevent ItSafety
- Do GLP-1 Drugs Cause Depression or Anxiety? The Trials Say No, the Records Say YesSafety
- GLP-1 Drugs in Pregnancy: What the Evidence Shows, and What It CannotSafety
- Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?Evidence
- Is CagriSema Better Than Semaglutide Alone? By 6.5 Points, Head to HeadEvidence
- Do GLP-1 Drugs Prevent Stroke? The Composite Moves, Stroke Alone Is ThinEvidence
- Retatrutide in Type 2 Diabetes: Why TRANSCEND-T2D-1 Reads Lower Than Phase 2Evidence
- Survodutide: What SYNCHRONIZE-1 Found, and Why It Reads Weaker Than Phase 2Evidence
- Ozempic Teeth: What Has Actually Been Measured, and What Has NotSafety
- Do GLP-1 Drugs Prevent Heart Attacks and Strokes? One, Not BothEvidence
- Weight-Loss Drugs in Hypertension: What the Cochrane Review LackedEvidence
- Does Semaglutide Help Liver Cirrhosis? Not in the Trial That Tested ItEvidence
- Can You Take a GLP-1 With Epilepsy? Seizure Risk Did Not RiseEvidence
- How Many Heart Attacks Could Semaglutide Prevent in the US?Evidence
- GLP-1 Use and Knee Replacement: Absolute Risk at Eight YearsEvidence
- Does Orforglipron Work for Type 2 Diabetes? Three Phase 3 TrialsEvidence
- Respiratory Side Effects of Weight-Loss Drugs: A Review of 123 StudiesSafety
- Is There a GLP-1 Pill That Works? Two Tablets, Two Different AnswersFormats
- Mortality in Serious Mental Illness: GLP-1 vs SGLT2 InhibitorsEvidence
- Can a Drug Prevent Muscle Loss on a GLP-1? Two Antibodies TestedEvidence
- What Is Ecnoglutide? A Phase 3 Result You Cannot Compare to the OthersEvidence
- Tirzepatide vs Semaglutide for Heart Failure, With and Without DiabetesEvidence
- Semaglutide and Effort in Major Depression: A 72-Person Randomized TrialEvidence
- Obesity Drugs Ranked Across 262 Trials: Weight Lost vs Side-Effect DropoutEvidence
- Do GLP-1 Drugs Help Psoriasis? Clear Skin in 40.6% Against 29.0%Evidence
- Do GLP-1 Drugs Cause Glaucoma? Nobody Untreated Was Ever ComparedSafety
- Frailty and Semaglutide's Cardiovascular Benefit in the SELECT TrialEvidence
- BMI Above 30 and Type 2 Diabetes Drug Response: Weight vs HbA1cEvidence
- Do GLP-1 Drugs Affect Breast Surgery? Implants Fared Worse, Flaps Did NotEvidence
- What Weight Loss Drugs Are There Besides Ozempic? Six Have EvidenceEvidence
- Do GLP-1 Drugs Help Resistant Hypertension? The Pressure MatchedEvidence
- Do GLP-1 Drugs Help COPD? Fewer Flare-Ups, Against One ComparatorEvidence
- GLP-1 Drugs in Psoriasis: Mortality, Heart Events and Substance UseEvidence
- Semaglutide and Reproductive Hormones in Rats: A Pair-Fed StudyEvidence
- Tirzepatide and Cardiac Remodeling in HFpEF: A 50-Patient Echo StudyEvidence
- Smart Scale Body Composition on GLP-1 Drugs: Fat vs Muscle LostEvidence
- Do GLP-1 Drugs Improve Blood Vessel Function? The Same Number, Two AnswersEvidence
- Frailty and Semaglutide in Heart Failure: The STEP-HFpEF AnalysisEvidence
- Liver Cancer Risk on GLP-1 Drugs vs Other Diabetes TreatmentsEvidence
- GLP-1 Drugs in MASH: Deaths, Ascites and a Small Liver Cancer SignalEvidence
- Can You Take a GLP-1 on Dialysis? 2,492 Patients, and No TrialEvidence
- Do GLP-1 Drugs Cause Pancreatic Cancer? Six Comparators, Five AnswersEvidence
- Do GLP-1 Drugs Help Parkinson's Disease? Prevention and Treatment DisagreeEvidence
- GLP-1 Prescribing to Children Aged 8 to 11: Who Gets ThemEvidence
- Real-World GLP-1 Weight Loss: Discontinuation, Dose and the Trial GapEvidence
- How Do You Take Oral Semaglutide? Empty Stomach, and Little WaterFormats
- Oral Semaglutide 50 mg in East Asian Adults: 14.3% Weight LossEvidence
- What Is Orforglipron? A Daily GLP-1 Tablet That Is Not a PeptideEvidence
- Do GLP-1 Drugs Help Heart Failure? Symptom Scores Rose 7.5 PointsEvidence
- Semaglutide and Fracture Risk: Type 2 Diabetes vs No DiabetesEvidence
- Semaglutide in Knee Osteoarthritis: A Six-Month Cohort and Its PhenotypesEvidence
- Semaglutide and Handgrip Strength: A 12-Month Body Composition StudyEvidence
- Semaglutide and NAION: Optic Nerve Risk in Diabetes vs ObesitySafety
- Is a Higher Semaglutide Dose Worth It? Three Points, Four Times the SymptomEvidence
- What Else Comes Back When You Stop a GLP-1? Almost EverythingEvidence
- Tirzepatide Dispensing by Dose in Japan: National Claims DataFormats
- SUMMIT Trial Composite Endpoint: Tirzepatide in HFpEF, Broken DownEvidence
- Tirzepatide vs Semaglutide: Major Adverse Liver Outcomes in Type 2 DiabetesEvidence
- UBT251 Triple Agonist: First-in-Human 12-Week Weight Loss TrialEvidence
- Do GLP-1 Drugs Cause Kidney Cancer? Trials Say Probably NotSafety
- Gallstone Risk on GLP-1 Drugs: Weight-Loss vs Diabetes TrialsSafety
- Do GLP-1 Drugs Help Knee Pain? Yes, and Read the Placebo ArmEvidence
- Do GLP-1 Drugs Cause Pancreatitis? Risk and Warning SignsSafety
- Do GLP-1 Drugs Affect Sex Drive? Nobody Has Run That TrialSafety
- Tirzepatide Sleep Apnea Trial (SURMOUNT-OSA): AHI Results at 52 WeeksEvidence
- Residual Stomach Contents on GLP-1 Drugs: A Gastric Ultrasound StudySafety
- Semaglutide Lean Mass in the SMART Trial: −2.5 kg, Interval Crossing ZeroEvidence
- FLOW Trial: Semaglutide 1.0 mg in Diabetic Chronic Kidney DiseaseEvidence
- Cochrane Review of Semaglutide for Obesity: 18 Trials GradedEvidence
- Tirzepatide and Oral Contraceptive Levels: 55 to 66% Lower PeaksSafety
- GLP-1 Seller Disclosure Gaps: Dose Pricing, State Coverage, FormatsFormats
- GLP-1 Sellers That Publish a Dose Price Ladder, CountedFormats